P-Cure, a global leader in precision oncology, proudly announces that Proton ARC therapy will become a routine option for patient treatments at Hadassah Medical Center as part of a Ministry of Health-approved clinical study.
MODIIN, Israel, Jan. 23, 2025 /PRNewswire-PRWeb/ -- P-Cure, a global leader in precision oncology, proudly announces that Proton ARC therapy will become a routine option for patient treatments at Hadassah Medical Center as part of a Ministry of Health-approved clinical study. This milestone marks a significant step forward in advancing cancer care, showcasing the clinical, physics, and economic benefits of this cutting-edge technology.
Proton ARC therapy is revolutionizing radiation treatment by delivering a highly conformal proton beam dose along an arc trajectory. This innovation ensures unparalleled precision, enabling maximum tumor targeting with multiple irradiation beamlets while sparing surrounding healthy tissues. The technology is particularly advantageous for complex cases and anatomies that challenge traditional approaches, including motion sensitive anatomical sites and tumors located near critical organs.
Prof. Aron Popovtzer, Head of the Sharett Institute of Oncology at Hadassah, remarked, "Proton ARC therapy is a game-changer. By delivering a conformal dose with unprecedented precision, we not only enhance clinical outcomes but also significantly reduce the risks of side effects for our patients. This is the future of radiation oncology, and we are thrilled to be at the forefront of its implementation."
Dr. Jon Feldman, Chief Medical Physicist at Hadassah, highlighted the comprehensive efforts of the clinical team in integrating arc therapy principles into the treatment arsenal. "This achievement reflects the dedication and expertise of our multidisciplinary team in making Proton ARC therapy a reality. We look forward to expanding the technology's use in the study cohort and beyond, bringing its benefits to a wider range of patients. All future new patients at our center will be planned both on classical fields and ARC-IMPT."
From a physics perspective, Proton ARC therapy leverages advanced beam delivery techniques to maximize dose conformity while minimizing radiation scatter. This precision reduces the risk of secondary malignancies and improves long-term outcomes, particularly critical in pediatric cases and for younger patients with long life expectations.
The economic benefits are equally compelling. Proton ARC therapy optimizes treatment efficiency, reducing the number of treatment sessions while maintaining superior clinical outcomes. This efficiency translates to lower operating costs for healthcare providers and patients, making proton therapy more accessible and sustainable.
Michael Marash, CEO of P-Cure, stated, "The integration of Proton ARC therapy into routine clinical practice underscores the versatility and innovation of P-Cure's proton therapy system. By addressing the challenges of space, cost, and accessibility, we are democratizing proton therapy and bringing this life-saving technology to more patients worldwide. This collaboration with Hadassah exemplifies how advanced technology can align with clinical excellence to transform cancer care."
About P-Cure
P-Cure is a leading provider of compact and innovative proton therapy solutions designed to enhance accessibility and precision in cancer treatment. With its groundbreaking technologies, P-Cure addresses the limitations of conventional systems, offering compact designs that fit into existing clinical settings without compromising treatment efficacy.
Proton therapy, including for proton active scanning therapy – the basis for ARC treatment -- is FDA-cleared for certain tumor localizations. Consult your healthcare provider for details about your specific treatment needs.
Media Contact
Stephen JACOBS, P-Cure, 1 9173468619, [email protected], www.p-cure.com
SOURCE P-Cure
Share this article